We identified T cell receptors (TCRs) targeting antigenic peptides that contain a shared β-catenin mutation (CTNNB1S37F) presented on common human leukocyte antigen alleles. TCR-engineered T cells eliminated patient-derived tumors and prevented relapse in vivo in mice, highlighting a strategy to exploit public neoantigens for TCR-based immunotherapy in solid cancers.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Parkhurst, M. R. et al. Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers. Cancer Discov. 9, 1022–1035 (2019). This paper reports that only 1.6% of somatic mutations in gastrointestinal tumors are recognized by tumor-infiltrating lymphocytes; 99% of these neoantigens are unique to the tumor.
Foldvari, Z., Brennan, M. S., Titov, A., Jacobsen, S. E. W. & Olweus, J. Targeting the roots of myeloid malignancies with T cell receptors. Nat. Rev. Cancer https://doi.org/10.1038/s41568-025-00857-0 (2025). This perspective presents key considerations for identifying and validating suitable target antigens and matching TCRs for treatment of myeloid malignancies with TCR-T cell therapies.
Strønen, E. et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 352, 1337–1341 (2016). This article shows that T cells from healthy donors can recognize neoantigens ignored by the tumor-infiltrating T cells of a patient.
Ali, M. et al. Induction of neoantigen-reactive T cells from healthy donors. Nat. Protoc. 14, 1926–1943 (2019). A protocol that describes how neoantigen-specific TCRs can be identified from naive T cell repertoires of healthy donors.
Foldvari, Z. et al. A systematic safety pipeline for selection of T-cell receptors to enter clinical use. NPJ Vaccines 8, 126 (2023). This report presents a stepwise approach for preclinical off-target screening of TCRs.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Eggebø, M. S. et al. TCR-engineered T cells targeting a shared β-catenin mutation eradicate solid tumors. Nat. Immunol. https://doi.org/10.1038/s41590-025-02252-1 (2025).
Rights and permissions
About this article
Cite this article
T cells engineered to target a shared β-catenin mutation eradicate solid tumors in mice. Nat Immunol 26, 1641–1642 (2025). https://doi.org/10.1038/s41590-025-02287-4
Published:
Issue date:
DOI: https://doi.org/10.1038/s41590-025-02287-4
